Medifast (MED) Q3 2026 Earnings Call: Coach Productivity Rises, Q4 Profitability Target Reaffirmed
Source Tradingkey
Key Takeaways
- Q3 2026 revenue fell 19.4% year over year to $72 million, within management’s guidance range, primarily due to a lower number of active earning coaches.
- Active earning coaches declined to approximately 10,200 from 19,500 a year earlier. However, average revenue per active earning coach increased 54.1% to $7,064.
- GAAP net loss widened to $17.5 million, or $1.57 per diluted share, reflecting lower gross profit and Project Catalyst restructuring costs. Adjusted net loss was $2.1 million, or $0.19 per diluted share.
- Medifast ended the quarter with $172.5 million in cash, cash equivalents and investments and no debt.
- Management expects Q4 revenue of $55 million to $75 million, EPS of $0.00 to $0.25, and adjusted EBITDA excluding interest income of $2 million to $6 million.
- Management said Medifast remains on track to deliver profitability in Q4 2026, supported by cost reductions and continued coach productivity growth, although coach count is expected to keep declining through year-end.
Key Financial Data
| Metric | Q3 2026 | Year-over-year change / context |
|---|---|---|
| Revenue | $72.0 million | Down 19.4%, mainly due to fewer active earning coaches |
| Active earning coaches | Approximately 10,200 | Down from 19,500 in Q3 2025 |
| Revenue per active earning coach | $7,064 | Up 54.1% |
| Gross profit | $50.0 million | Down 19.5% |
| Gross margin | 69.5% | Unchanged year over year; included 230 basis points of Catalyst charges |
| Adjusted gross profit | $51.7 million | Down 16.9% |
| Adjusted gross margin | 71.7% | Up 220 basis points |
| SG&A expense | $69.4 million | Up 4.8%, including $13.8 million of Catalyst restructuring charges |
| Adjusted SG&A | $55.6 million | Down 16.0% |
| Operating loss | $19.4 million | Versus a $4.1 million loss in Q3 2025 |
| Adjusted operating loss | $4.0 million | Improved 3.2% |
| Net loss | $17.5 million | Versus a $2.3 million loss a year earlier |
| Diluted EPS | -$1.57 | Versus -$0.21 in Q3 2025 |
| Adjusted diluted EPS | -$0.19 | Adjusted net loss of $2.1 million |
| Adjusted EBITDA | $0.4 million | Up 29.7% |
| Cash, cash equivalents and investments | $172.5 million | No debt at September 30, 2026 |
Business and Operating Performance
Disclaimer: For information purposes only. Past performance is not indicative of future results.
Recommended Articles
Today’s Market Recap: Dow Gains Over 1%, SpaceX Surges More Than 8% After Hours, Supermicro Jumps Over 14%, Netflix Falls More Than 5%Tracking the Market TrendTradingKey - As of the close on October 20 Eastern Time, the Dow Jones Industrial Average rose 1.02% to 52,495.88, the Nasdaq Composite slipped 0.02% to 26,424.82, and the S&P
Tracking the Market TrendTradingKey - As of the close on October 20 Eastern Time, the Dow Jones Industrial Average rose 1.02% to 52,495.88, the Nasdaq Composite slipped 0.02% to 26,424.82, and the S&P
SpaceX’s latest earnings have given Wall Street a reason to revisit AI hardware stocks. Elon Musk’s company is preparing to spend billions more on computing infrastructure, and three US-listed stocks
Bitcoin has recovered to around $82,500 after briefly falling below $80,000 last week.But the rebound faces a major test on Wednesday, when fresh US oil inventory data could revive the inflation fears
TradingKey - Tesla (TSLA) will report its third-quarter 2026 financial results after the U.S. stock market close on October 21, Eastern Time, and host an earnings conference call at 17:30 that day. Th
SpaceX Stock Price Forecast: Rebounds to $148 Ahead of Earnings, $152–$160 Becomes Key Resistance ZoneTradingKey - As of the close on Monday (October 19) Eastern Time, SpaceX (SPCX) closed at $147.96, up 1.32% on the day, reaching an intraday high of $151.01. The closing price was noticeably under pre
TradingKey - As of the close on Monday (October 19) Eastern Time, SpaceX (SPCX) closed at $147.96, up 1.32% on the day, reaching an intraday high of $151.01. The closing price was noticeably under pre
